Cytokines are polypeptides with a molecular weight of 10-45 kDa. Like the endocrine hormones, they are highly potent molecules, active at picomolar and femtomolar concentrations, that affect cellular responses distal to the site of secretion. However, unlike hormones whose main purpose is to maintain the homeostatic balances, cytokines are synthesized by cells in response to infection, inflammation or trauma (1) (2) (3) . Cytokine research began with the observation that antigen exposure induces lymphocytes to release substances that inhibit migration of macrophages and studies on endogenous pyrogen, the fever-causing molecule produced by inflammatory cells (4) (5) (6) . Since then, a large number of polypeptides with a wide range of immunomodulatory and growthstimulatory properties have been characterized. This has resulted in an increasingly complicated nomenclature. In 1969, Dumonde first introduced the term "Iymphokine" to describe the products of sensitized lymphocytes (7) . The subsequent knowledge that several cell types other than lymphocytes also produce these factors, gave way to the term "cytokines" (8) . A few years later, the second international Iymphokine workshop proposed the term "interleukin" to indicate the ability of these proteins to act as communication signals between different populations of leukocytes (9) . Since then, at least 13 cytokines have been designated as interleukins (10) . However, several important cytokines which would qualify to be inteleukins (tumor necrosis factor, interferon, transforming growth factor and most colony stimulating factors) continue to be known by their original names (10) . Therefore, the term "cytokines" is generally preferred by most researchers in this field.
Inflammation is characterized by the accumulation of neutrophils and mononuclear phagocytic cells at the site of injury, and release of various mediator molecules. Although neutrophils are the dominant. cell type, neutrophils have a limited ability to synthesize cytokines compared to the monocyte/macrophage cell population. The blood mononuclear population is comprised of monocytes, natural killer cells, but mostly T lymphocytes. Small-size monocytes newly exiting the bone marrow produce less cytokines than the more mature and large cells. Activated monocytes release several polypeptides of which interleukin-1 (IL-1) and tumor necrosis factor (TNF) are the most potent and possess a broad range of biological properties associated with acute and chronic inflammatory changes (3) . It is the monocytes, however that account for most of the cytokine production by these mixed cell populations. Therefore, most studies of the effects of chronic hemodialysis (HD) on cytokine production have dealt with the peripheral blood mononuclear cells (PBMC).
The magnitude of changes in blood constituents after exposure to the dialysis membrane has been used as an index of "biocompatibility" (11) (12) . In an attempt to study markers of biocompatibility, several groups have examined the effect of different dialysis membranes on complement activation, neutrophil degranulation, cytokine production, lymphocyte activation, protein adsorption and {32 microglobulin production and clearance (reviewed in 11, 12) . This review will focus on cytokine production during hemodialysis.
During hemodialysis human blood leukocytes come into contact with several exogenous challenges, including the surface material of the dialyzer membrane, soluble membrane constituents, complement or other plasma products activated by the dialyzer materials, microbial products or solutes in the dialysis bath, and the effect of pumping blood into the HD circuit (2-3). These interactions lead to the production of a variety of pro-inflammatory cytokines. in 1983, the "Interleukin Hypothesis" was proposed, incriminating interleukin-1 (IL-1) produced during dialysis, as the cause of hypotension, fever and other acute phase responses observed in patients on dialysis (13) . However, over the last decade the discovery of newer cytokines and cytokine-specific inhibitory proteins, have mandated a re-evaluation of this hypothesis. This review will be restricted to the factors that effect the production of pro-inflammatory cytokines and specific inhibitory proteins in patients on dialysis and their role in the biocompatibility of dialysis membranes.
Several of the acute and chronic metabolic and inflammatory changes associated with hemodialysis are also observed in other diseases, namely rheumatoid arthritis, inflammatory bowel disease, some chronic infections and cancers, and various collagen vascular diseases (reviewed in 1). Long-term HD is often associated with a more progressive aging process and it is speculated that this is also linked to increased cytokine production in these patients (14) . The similarities between the biological properties of the pro-inflammatory cytokines and the clinical symptoms observed in patients on HD have lent support to the concept that these cytokines may play a role in dialysis-related symptoms.
Tumor necrosis factor (TNF) was first shown to cause a shock-like syndrome in animals (15) . However when injected into humans at low concentrations (less than 1 tIg/kg), TNF produced hypotension and leukopenia as well as several metabolic dysfunctions. Similarly, IL-1 was shown to produce fever and hypotension in rabbits (16) . Humans receiving only 1 ng/kg of IL-1 develop fever and with increasing doses of 100 ng/kg, hypotension (17, 18) . Interleukin-1 and TNF are highly synergistic in both animal and in vitro studies. IL-1 and TNF act synergistically in the production of hemodynamic shock (16) , eicosanoid synthesis and cell toxicity. The increased synthesis of lipid metabolites such as the prostaglandins as well as platelet activating factor by IL-1 and TNF contribute to the shock syndrome (19) . Hypotension, neutropenia, thrombocytopenia, lactic acidosis and decreased systemic vascular resistance are observed following an intravenous injection of the combination of TNF and IL-1 (16) . IL-1 plus TNF enhance endothelial procoagulant activity, the expression of leukocyte adhesion molecules and synthesis of a plasminogen activator inhibitor. In addition to triggering events in the central nervous system leading to fever, IL-1 and TNF also trigger the release of a variety of neuropeptides, most importantly ACTH, corticotropin releasing factor, and somatostatin. Although IL-1 and TNF are appetite suppressants, their mechanism of action as anorectic agents is thought to be due to peripheral effects on hepatic metabolism rather than in the central nervous system. IL-1 and TNF induce a rapid increase in slow 294 wave sleep, even before the onset of fever suggesting that the lethargy in patients after dialysis could be due to the effects of these two cytokines (2, 3) .
Whereas IL-1 and TNF up-regulate cellular metabolism and increased expression of several genes coding for biologically active molecules, some genes, particularly those for albumin, lipoprotein lipase, cytochrome P450 and aromatase, are suppressed by IL-1 and TNF. IL-1 and TNF predominantly activate transcription of several genes but also stabilize mRNA for others, both events leading to increased new protein synthesis. In the liver, IL-1 and TNF upregulate the transcription of several hepatic acute phase proteins such as a-2-acid glicoprotein and a-2-macroglobulin. Interleukin-1 also initiates the transcription of serum amyloid A. This is a direct effect of IL-1 on hepatocytes, but other effects of IL-1 on hepatic protein synthesis are due to IL-1 induced IL-6 production (2, 3). Inteleukin-1 and TNF also reduce gene expression for lipoprotein lipase and at the same time increase hepatic fatty acid synthesis (20, 21) .
Mechanisms of antagonizing cytokine effects
Several naturally occurring specific and non-specific inhibitors of cytokines have been characterized. These inhibitors could alter the biological relevance of a given cytokine present in plasma, and in some cases interfere with measurements of cytokine level. Lipoproteins, lipids, and a a-2 macroglobulin are examples of naturally occurring non-specific inhibitors of cytokines such as IL-1, IL-2 and IL-6 (1). Further, in response to a variety of stimuli, the same cells that synthesize IL-1 and TNF, also produce molecules which block the action of these potent inflammatory cytokines. The interleukln-t receptor antagonist (IL-1 Ra) and soluble TNF receptors (TNFsR) are examples of these.
IL-1 receptor antagonist (IL-1 Ra):
Polypeptides which specifically inhibit IL-1 have been detected in the serum of humans injected with bacterial endotoxin (22) , urine of febrile patients (23), supernatants of human monocytes adhering to IgG coated surfaces (24) and urine of patients with monocytic leukemia (25) . Using an IL-1inhibitor purified from adherent monocytes (24, 26) , a cDNA of the molecule was cloned (27, 28) which coded for a polypeptide of approximately 17 kDcf with a 26% amino acid homo1-ogy to IL-1j3 and a 19% homology to IL-1a. Conserved amino acids revealed a 41% homology of the IL-1Ra to IL-1j3 and 30% to IL-1a (1) . Similar to the naturally occurring IL-1 urinary inhibitor, (29) the recombinant IL-1 inhibitor competes with the binding of IL-1 to its cell surface receptors. Because of its sequence homology and mode of activity, the IL-1 inhibitor was renamed the IL-1 receptor antagonist (IL-Ra). There are two IL-1 cell surface receptors. The type I receptor (IL-1RI) is found on most cells, and the type II receptor (I L-1 RII) is found primarily on neutrophils, monocytes, bone marrow cells and B-cells (30) . The type I receptor has a greater affinity for IL-1a than IL-1j3, and the type II receptor has a greater affinity for IL-1j3 than IL-1a.
IL-1 Ra blocks IL-1 activity in vitro and in vivo. In vitro, the IL-1 Ra apperas to occu py the IL-1 type I receptor on T-cells and fibroblasts with nearly the same affinity as that for bona fide IL-1 but without agonist activity (26) . The human IL-1Ra also blocks the binding of IL-1 to human cells bearing the IL-1 type II receptor such as neutrophils and B-cells (31) as well as human peripheral myelomonocytic leukemia cells (32) . Using murine T-cells (I L-1RI), the human IL-1 Ra blocks the binding of IL-1 at nearly equimolar concentration; however, a 40-fold molar excess of the IL-1Ra is required to block the binding of IL-1 to human neutrophils or monocytes (I L-RII) (31) . When IL-1Ra occupies the type I receptor, there is no evidence of internalization nor of protein kinase activity (33) . Recombinant IL-1 Ra blocks the biological activity of IL-1 in various animal models of disease. Rabbits (34) or baboons (35) injected with IL-1 develop hypotension which is reversed by prior administration of the IL-1Ra. However, during sepsis several cytokines are produced and hence the question whether specific blockade of IL-1 is sufficient, remains unanswered. Using large doses of IL-1Ra with blood levels in the range of 20-30 pg/ml, the shock-like state induced by either Gram-positive or Gram-negative organisms is reversed (37, 37) . The results of several other studies have demonstrated that specific IL-1 receptor blockade significantly reduces the severity of several inflammatory diseases (38) .
Relative production of IL-1 and IL-1Ra: The ratio of IL-1 to IL-1Ra in vivo may be critical to the outcome of disease. IL-1Ra is synthesized in septic animals and humans with a variety of infectious or inflammatory diseases. The balance between the amount and secretion of IL-1 and its receptor antagonist may be critical in some diseases. It is evident from studies in both health and disease, that IL-1 and IL-1Ra gene expression and protein synthesis are differently regulated (24, 39, 40) . Interleukin-1j3 is transcribed and synthesized in cells before IL-1Ra. This is further supported by studies that demonstrated spontaneous gene expression for IL-1j3 and IL-1Ra in fresh cells from patients with acute myelogenous leukemia (32) . Cells from each of the 11 patients studied spontaneously expressed the gene for IL-1j3. In contrast, the leukemic cells from only one of 11 patients expressed IL-1 Ra following stimulation. Unlike IL-1, IL-1 Ra has a classical signal peptide and is readily secreted into the extracellular compartment. In contrast, only 50% of the IL-1j3 and less than 10% of IL-1a is secreted. An intercellular form of IL-1 Ra without a signal peptide has been described in keratinocytes (41) and it is speculated than intracellular IL-1Ra in these cells acts to counter the biological activity of IL-1a which remains in the cytosolic compartment of keratinocytes. However, this is not the case in human monocytes stimulated with endotoxin where nearly all of the IL-1a is intracellular but less than 10% of IL-1Ra remains in these cells. Nevertheless, intracellular IL-1a may be biologically active and could have an autocrine role (30, 42) . Hence, the balance of IL-1 to IL-1 Ra should be considered for both intracellular and extracellular compartments.
During experimental endotoxemia in humans, levels of IL-1j3 reach a maximal concentration of 150-200 pg/ml after 3-4 hours, and then fall rapidly; in these same individuals, the peak levels of IL-1Ra occur after 4 hours, exceed the molar concentration of IL-113 by 100-fold and are sustained for 12 hours (43) . In critically ill patients with sepsis, plasma IL-1 Ra correlated directly with the APACHE II scores (44) . Further, peak plasma levels of IL-1Ra did not differ significantly among patients who survived and those who died (44) . Likewise, in baboons administered lethal E. coli challenge, plasma IL-1Ra levels peaked at 4-6 hours and were sustained for 24-28 hours. In contrast, peak IL-1j3 levels were lower and returned to baseline much earlier than IL-1Ra (44) . Although IL-1Ra levels were 5 to 10-fold higher than IL-1, they are unlikely to be adequate to block the tissue effect of IL-1j3.
These data suggest that the production of IL-1 Ra serves as a marker of the severity of disease and may not constitute an adequate protective response against the inflammatory actions of IL-1.
TNF soluble receptors (TNFsR): As in the case of IL-1Ra, the presence of naturally occurring inhibitors to TNF have been identified. The TNF-specific inhibitors block the cytotoxic and inflammatory actions of TNF in vitro and in vivo (45) (46) (47) . Two such inhibitors have since been purified from human urine (48) . These have been shown to be the extracellular domains of two cell surface TNF receptors by amino acid sequence analysis (49) and are therefore TNF soluble receptors (TNFsR) corresponding to the p55 and p75 cell surface TNF receptors. The TNFsRp55 (also referred to as type I) is a cysteine rich glycoprotein, and the TNFsRp75 (also referred to as type II) is identical to the extracellular ligand-binding domain of the p75 TNF receptor. The TNFsR are proteolytic cleavage products and not separate products of alternate mRNA splicing.
Circulating levels of cytokines in hemodialysis patients
Using biological assays, several groups have independently demonstrated that patients undergoing dialysis using routine regenerated cellulose membranes had evidence of elevated IL-1 and TNF levels before a dialysis session and, in some studies, a further increase at the end of the procedure (50) (51) (52) (53) (54) . In some studies, specific immunoassays have been used (52) . Interestingly, patients with ESRD but not treated with hemodialysis did not show evidence of elevated IL-1 levels (52) leading to the conclusion that the hemodialysis procedure rather than renal failure pe-r se leads to increased IL-1 production. Interleukin-6 has also been reported elevated in patients on chronic HD but not in patients with ESRD not on dialysis treatment (55) . However, others have failed to show significantly elevated IL-1 or TNF in the plasma of HD patients both before and after dialysis, when compared to healthy controls, even using optimal methods of detection and extraction (56, 57) .
In general, the elevated levels of cytokines as determined by biological assay have not been confirmed by specific radioimmunoassay and ELISA. The levels reported for cytokines in HD patients have not 296 been high. In fact, humans undergoing a strenuous exercise have higher levels. The failure to detect uniformly elevated levels of IL-1j3 in HD patients could be due several factors. First, dialysis induced cytokine release may be transient. An example of this is experimental endotoxemia in humans. TNF is only transiently elevated (30 minutes) after an injection of LPS (58) . Only a single time point (180 minutes) after LPS is associated with significant IL-1j3 levels (59) . Multiple, frequent measurements are suggested for demonstrating elevated cytokines in the circulation during disease (60) . Second, a significant proportion of the IL-1 synthesized remains intracellular and is not released into plasma (40) . Third, poor nutrition and anemia in renal failure and HD are associated with decreased cytokine production. In fact, in HD patients, treated with erythropoietin, there was 5-fold increase in the production of TNF, interferon, colony stimulating factors, and IL-2 from mononuclear cells stimulated in vitro (61) . Fourth, coexisting conditions such as acute and chronic infections, autoimmune diseases, immunosuppressive therapy, blood transfusions etc. could influence the circulating cytokine levels. Lastly, as in the healthy population, there probably exists a wide spectrum in the cytokineproducing ability among dialysis patients, ranging from low or normal to high. In the case of circulating levels, some healthy volunteers injected with endotoxin will have no detectable increase in circulating IL-1j3 levels compared to others who have a 3-5 fold increase above baseline measurements. We believe this variation also exists in the dialysis population and could reflect the variation in the release of this cytokine from PBMC. Indeed, we have observed a wide variation in PBMC production of IL-1j3 among the hemodialysis patients as well as healthy volunteers.
Specific radioimmunoassays and ELISA for various cytokines have been used to reevaluate the significance of plasma cytokine levels in patients on HD. Taking these into account and using double chloroform extraction, we studied a selected group of undialyzed patients with advanced chronic renal failure (CRF) and patients on chronic ambulatory peritoneal dialysis (CAPD) and HD. Plasma levels ofIL-1j3, TNFa, IL-1Ra and TNFsRp55 were found to be elevated in all three groups of patients when compared to healthy controls. There were however, no significant differences between the levels in undialyzed patients with CRF, patients treated with CAPD or predialysis blood in patients on HD (62, 63) . Further, in undialyzed patients with varying degrees of renal insufficiency, plasma cytokine levels strongly correlated with the severity of renal insufficiency (62, 64) . These data suggest that the elevated plasma levels of cytokines in undialyzed patients with CRF and patients on CAPD or HD reflect inadequate clearance rather than increased production. Fig. 1) Circulating mononuclear cells are more likely to yield consistent results regarding increased cytokine production than circulating plasma levels. Several groups have reported that patients undergoing chronic HD show signs of mononuclear cell activation. Interleukin-1 is present in the mononuclear cells of patients on dialysis (54, (65) (66) (67) . In contrast, mononuclear cells isolated from healthy subjects do not contain IL-1 protein nor mRNA, for IL-1 using northern hybridization or PCR. Even after 24 hours of incubation, there is no evidence of IL-1 synthesis in the mononuclear cells of healthy donors (68) (69) (70) . However, incubation of mononuclear cells from patients undergoing chronic hemodialysis in the absence of exogenous stimuli results in spontaneous IL-1 production (66, 67) . When these cells are stimulated with LPS, they produce as much as 5-fold more IL-1 compared to mononuclear cells from normal subjects (54, (65) (66) (67) . Similar results have been reported for the production of TNF and IL-6 (71-73). Thus, these studies demonstrate that patients on HD treatment have circulating mononuclear cells that are in a state of activation.
Production of cytokines by mononuclear cells in patients on chronic hemodialysis (
There is support for this concept by measuring gene expression for IL-1 and TNF in cells passing through the dialyzer in patients. Mononuclear cells removed from the arterial inlet of the dialyzer contain a small but significant amount of IL-1J3 and TNFa (74, 75) . However, after 5 minutes of HD through a first use cuprophan dialyzer, the mononuclear cells in the blood exiting the dialyzer have initiated transcription to express large amounts of IL-1J3 and TNFa. Interestingly, the mononuclear cells returning to the dialyzer from the arterial side do not show evidence of IL-1 gene expression (74) . A single passage through a cuprophan membrane is apparently sufficient to trigger transcription and once activated, the mononuclear cells do not return into the circulation within the time frame of the dialysis session. Usig the same methods, cytokine genes are not activated by noncomplement activating membranes during both in vitro and clinical dialysis (74, 76) .
Unlike most proteins, cytokine production can be clearly divided into two independent events: mRNA synthesis, and translation into protein, each event requiring a separate signal (76) . Thus, in patients undergoing routine cuprophan hemodialysis, gene expression may take place even in the absence of contaminated dialysate. These cells can either degrade their mRNA without translation into cytokine protein or receive a second signal from ongoing infection or illness, which leads to enhanced synthesis of the cytokine. Human mononuclear cells "primed" in vitro by exposure to recombinant C5a produced more IL-1 and TNF when exposed to low concentrations of LPS (5-10 pg/ml) than cells from controls (76) (77) . A second signal such as endotoxin could be provided by endogenous or exogenous sources. However, the most likely source of a second signal is the dialysate itself. In the absence of a second stimulus, it is unclear where the mRNA-primed mononuclear cells exit the circulation during the 5 hours of HD. Certainly, a large pool of cells could be adhering to endothelium, particularly in the lung. However, receptors on monocytes and adhesion molecules on endothelial cells may attract activated monocytes to the synovium or into other tissues.
Role of complement activation on cytokine production
In vitro studies support the concept that monocytes become activated on the dialysis membrane by factors such as generation of complement or the intrinsic nature of the dialysis material. Considerable attention has focused on complement activation since two of the complement products, C5a and C3a, which when purified from human plasma, have been shown to stimulate cytokine synthesis (78) . Present data clouds this issue since recombinant C5a, while possessing neutrophil activating properties, does not trigger significant IL-1 or TNF synthesis (76) . This issue is not yet resolved since recombinant C5a is not glycosylated whereas natural C5a is. Nevertheless, there seems to be an important synergism of C5a and edotoxin in the generation of cytokines, regardless of whether the C5a is recombinant or natural (79) .
During in vitro HD, when human blood is circulated in the blood compartment of a hollow fiber cuprophan dialyzer, transcription into mRNA is apparent within 2 hours. However, in the absence of endotoxin in the dialysate, there is no translation into IL-1 protein (76). This mRNA is rapidly and more efficiently translated when exposed to low concentrations of endotoxin compared to cells exposed to endotoxin only. Thus, 2 hours of hemodialysis results in mRNA synthesis and the cell is considered "primed" for subsequent cytokine synthesis. Likewise, recombinant C5a stimulates IL-1 and TNF gene expression without significant translation into cytokine protein (76) . However, in the presence of substimulatory concentrations of endotoxin (5-10 pg/ml) in a serum-free culture, the addition of recombinant C5a amplifies the signal and results in enhanced IL-1 and TNF synthesis (77) .
Role of endotoxin and other dialysate products on cytokine production
The LAL test is not a useful tool to study the potential role of the transmembrane passage of dialysate-derived pyrogens. Hence, cytokine production has been used as an index of the passage of endotoxins across dialyzer (80) (81) (82) (83) (84) . Fresh, heparinized human blood was circulated through a closed circuit cuprophan dialyzer and the dialysate compartment was challenged with either pyrogen-free saline or saline that was purposefully contaminated with purified lipopolysaccharide (LPS) extracted from E. coli. After in vitro dialysis, PBMC were harvested and incubated for 24 hours. Interleukin-1 production by PBMC was observed only when the dialysate was challenged with LPS (81). These observations have been confirmed by others using bacterial filtrates in the dialysate (80, 82) . Other studies demonstrated that the IL-1 inducing activity found in the blood compartment was prevented by polymyxin B, a cationic peptide which binds the lipid A moiety of LPS, suggesting that lipid A fragments did cross the membrane (80, 82) . More recently Lonnemann and colleagues have compared the transmembrane passage of TNFa-inducing substances in Pseudomonas maltophilia filtrate, across regenerated cellulose membranes with highflux membranes (83) . When the dialysate was challenged with Pseudomonas maltophilia filtrate, TNFainducing activity in the blood compartment containing 10% fresh plasma, increased significantly with regenerated cellulose membranes and to a lesser extent with polyacrilonitrile and cellulose triacetate membranes. In contrast, no increase was observed in the blood compartment of polysulfone and polyamide membranes. It was speculated that the hydrophobic domains of pyrogenic material result in effective adsorption (84) . However, plasma coating of the dialyzer membranes during the sterile phase of each experiment could have influenced the pyrogen permeability differently for each membrane. Thus, some membranes may be more effective than others in rejecting cytokine-inducing substances derived from water bacteria (84) .
Small molecular weight fragments of LPS containing two fatty acids (j3-hydroxymyristic acid) linked to phosphorylated and acetylated glucosamine disacchari des are the minimal structures required for mono-cyte stimulation of IL-1 and TNF production (85) . Although the molecular weight of these fragments is approximately 2 kDa, their three dimensional structure and ionic interactions, with dialysis membranes are more relevant than their calculated molecular size. The passage of endotoxin-like IL-1-inducing substances into the blood compartment are further supported by studies showing a similar passage of radiolabelled LPS added to the dialysate compartment into the blood circuit, across cuprophan, AN69 and polysulfone membranes (86, 87) . Within 15 minutes, between 1 and 5% of the radiolabelled LPS can be found in the blood side during in vitro HD. With time, the amount increases to 10-20%. Studies also suggest that fragments of LPS activate monocyte cytokine production without being reactive in the LAL (88) . The molecular weight of the labeled framents is low (2-4kDa) and passage takes place using membrane made from cuprophan, polyamide or polysulfone. The amount of LPS which binds to the membranes is also dependent of the type of polymer, with cuprophan binding the least (86) . It should be noted that studies using radiolabelled LPS may not be comparable to studies measuring the biological activities of LPS, such as induction of cytokines. Finally, another explanation for the failure of LAL reactivity to correlate with induction of cytokines in the blood compartment is that nonendotoxic microbial products are potent inducers of IL-1 and TNF. One such candidate is the low molecular weight Pseudomonas exotoxin which passes through the intact dialysis membrane from the dialysate.
Lonnemann and colleagues studies the passage of IL-1-inducing activity across cuprophan dialyzers using E. coli-contamined dialysate (80) . Within the time frame of the experiment, when tissue culture medium or 5% albumin was circulated in the blood compartment, IL-1 inducing activity was not observed. In contrast, when 10% plasma was circulated in the blood compartment, IL-1 inducing activity was observed within 15 minutes (80) . The explanation for this phenomenon could be that plasma proteins "capture" LPS derived from the contaminated dialysate, making it available to mononuclear cells, leading to cytokine production. Hepatic LPS binding protein (LBP) binds LPS and facilitates the induction of IL~1 and TNF (89) (90) (91) . LBP has a molecular weight of 60 kDa and is constitutively synthesized by the liver. It binds to LPS with the same affinity as polymyxin B (Fig. 2) . However, unlike polymyxin B, LPB enhances LPS-induced activity in monocytes. The carboxyl end of LBP molecule binds LPS, a site distinct from the LPS binding location recognized by cell-determinant 14 (CD14) on the surface of monocytes, neutrophils and some B-cells (92) (93) (94) (95) . Thus for optional cytokine induction, both LBP and CD14 need to be considered. Although it is conceivable that the patients with low levels of LBP and/or low expression of CD14 on monocytes would have a decreased cytokine response to LPS, in fact, patients on chronic HD have 2-3-fold higher circulating levels of LBP than healthy subjects.
Several studies demonstrate that apoliproteins such as HDL bind LPS and render it unavailable biologically. In addition to naturally occurring LBP that facilitates LPS-induced cytokine production, another naturally occurring molecule, bactericidal/ permeability increasing factor (BPI) has been shown to bind to LPS with the same affinity as polymyxin Band LBP (Fig. 2) . However, unlike LBP, BPI does not bind to CD14, and "neutralizes" the biological effects of LPS (97, 98) . BPI is released from the neutrophil granules upon stimulation with a variety of stimulants. The balance between these two molecules (LBP and BPI) adds another interesting dimension to cytokine production in dialysis patients.
Cytokine-specific inhibitory proteins in dialysis patients (Fig. 1) Plasma IL-1Ra and TNFsR levels have been studied in patients with chronic renal failure, on chronic hemodialysis and chronic ambulatory peritoneal dialysis. In HD patients, plasma levels of pro-inflammatory cytokines (IL-1,B and TNFa) although higher, are not significantly higher than those in healthy controls (62, 63) . However, in the same patients, plasma levels of cytokine-specific proteins (IL-1 Ra and TNFsRp55) were significantly higher than those in healthy controls. In fact, the levels of IL-1Ra and TNFsR were several fold higher than IL-1,B and TNFa respectively.
Studies that have measured the production of IL-1 B and IL-1 Ra by PBMC have shown that a) in patients on chronic HD with reused cuprophan membranes, content of IL-1Ra in freshly obtained PBMC is higher than that in patients with CRF, CAPD patients or healthy controls; b) production of IL-1Ra by endotoxin-stimulated PBMC from these HD patients is threefold higher than that in patients with CRF, CAPD patients or healthy controls; and c) endotoxin-stimulated PBMC from all three groups of patients with renal failure produce significantly more IL-1Ra than IL-1,B (99) . These data indicate that patients on chronic hemodialysis with reused cuprophan membranes have a heightened production of IL-1Ra in unstimulated PBMC, another indicator of monocyte activation in this population. The stimulus for the increased production of IL-1 Ra in hemodialysis patients is unclear. It is likely that the production of both IL-1,B and IL-1Ra are induced by the same stimuli associated with hemodialysis.
Biological responses to IL-1 can be induced by occupancy of a few as 5% of IL-1 receptors, and a 50-100 molar excess of IL-1Ra is required to inhibit 50% of IL-1 induced responses in vitro (1, 38) . In vivo a 10,000-fold excess of IL-1Ra is required (38) . Therefore, it is unlikely that the elevated levels of IL-1Ra observed in HD patients are high enough to reduce the biological effects of IL-1 induced during hemodialysis. Andersson and colleagues have shown that in endotoxin-stimulated monocytes, IL-1 al,B and IL-1Ra are produced concurrently by the same cell (100) . We have observed that in undialyzed and dialyzed patients with CRF, IL-1 Ra production by endotoxin stimulated PBMC is closely correlated with 300 IL-1,B production (101) . Hence, the elevated IL-1Ra production in these patients may be a reflection of the host inflammatory response, and IL-1Ra may be a better indicator of the host response to the cyokineinducing stimuli encountered during hemodialysis, than IL-1. This phenomenon of increased IL-1Ra production by PBMC from HD patients requires confirmation, particularly since the population studied reused cuprophan membranes (99) .
